← FDA DRUG APPROVALS

FDA ANDA · ANDA084300

CYCLOMYDRIL

cyclopentolate hydrochloride and phenylephrine hydrochloride

Sponsor: ALCON LABS INC

APPLICATION
ANDA084300
TYPE
ANDA
ORIGINAL APPROVAL
1975-09-12
LATEST ACTION
2025-05-02
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription

Products

CYCLOMYDRIL · ReferencePrescription
CYCLOPENTOLATE HYDROCHLORIDE 0.2%, PHENYLEPHRINE HYDROCHLORIDE 1% · SOLUTION/DROPS · OPHTHALMIC

Approval history

2025-05-02Labeling · Supplement 44 · standardAP
2003-10-31Labeling · Supplement 32AP
2002-12-23Manufacturing (CMC) · Supplement 29AP
2002-12-19Manufacturing (CMC) · Supplement 30AP
2001-04-18Manufacturing (CMC) · Supplement 27AP
2001-04-18Manufacturing (CMC) · Supplement 25AP
2001-04-18Manufacturing (CMC) · Supplement 26AP
2001-04-18Manufacturing (CMC) · Supplement 24AP
2000-04-28Manufacturing (CMC) · Supplement 23AP
2000-04-07Manufacturing (CMC) · Supplement 28AP
1999-05-07Manufacturing (CMC) · Supplement 21AP
1999-03-23Manufacturing (CMC) · Supplement 22AP
1999-03-04Manufacturing (CMC) · Supplement 20AP
1996-12-24Labeling · Supplement 11AP
1996-12-24Labeling · Supplement 14AP
1996-04-03Manufacturing (CMC) · Supplement 17AP
1996-03-18Manufacturing (CMC) · Supplement 19AP
1996-03-18Manufacturing (CMC) · Supplement 18AP
1995-10-05Manufacturing (CMC) · Supplement 16AP
1994-08-04Manufacturing (CMC) · Supplement 15AP
1993-06-04Manufacturing (CMC) · Supplement 12AP
1993-06-04Manufacturing (CMC) · Supplement 10AP
1992-11-05Manufacturing (CMC) · Supplement 13AP
1989-03-24Labeling · Supplement 9AP
1989-03-09Manufacturing (CMC) · Supplement 6AP
1985-12-17Manufacturing (CMC) · Supplement 4AP
1975-09-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →